Five Pharma Names Re-Rated Higher This Week. Their Prices Fell. That's Not a Coincidence.

7 Jul 2026 · DAILY NOTE

Two groups of stocks moved in exactly opposite directions over the past few trading days, and the difference between them is the whole game.

The Quiet Group

Merck climbed from a score of 62 to 73 while its price fell 2.1%. Novo Nordisk jumped from 44 to 58 while dropping 2.3%. Amgen moved from 58 to 72 — a 14-point jump — while the stock lost ground. Bristol-Myers Squibb rose 11 points to 86, one of the highest scores on the board, as its price slid 2.5%. Pfizer added 4 points to reach 91 on a 2.5% pullback.

None of these stocks did anything dramatic. They went nowhere, or slightly down. That is exactly why their scores climbed — a falling price relative to a name's own recent average is what the scoring model is built to reward. Five pharma and healthcare names re-rated meaningfully higher in the same week their charts looked the most unremarkable. Nobody was watching. That is usually the point.

The Loud Group

AMD ran 6.6% in the same window and its score fell 6 points to 80. Qualcomm gained 5.8% and dropped 2 points to 96 — still a strong score, but moving the wrong way. Arista Networks rose 8.3% while shedding 2 points. CoreWeave gained 5.8% while losing 5 points to 89. Circle rallied 6.2% while falling 9 points to 81.

These aren't bad businesses and a falling score isn't a sell signal by itself — it is the model saying the same thing in every case: the easy entry already happened. A stock can be up sharply and still be a worse buy today than it was a week ago, because the distance between price and trend has widened, not narrowed. That's the entire mechanism, and this week's board is as clean an illustration of it as you'll see.

Why the Same Week Produces Both

This isn't a healthcare-versus-tech story and it isn't a prediction about either group. It's what happens whenever a market has multiple things happening under the surface at once: capital rotating quietly into a beaten-down sector nobody's excited about, while a handful of already-strong names keep getting more expensive relative to their own trend on that name's own momentum. The scoring model doesn't know or care about the narrative in either group. It only measures distance from trend, and this week that measurement moved five pharma names toward the buy zone and five momentum names away from it, at the same time as their prices did the opposite.

What's Actually Actionable Here

Bristol-Myers Squibb at 86 and Pfizer at 91 are both in the deep entry zone after this pullback, priced lower than they were days ago while their setups improved — that combination is the profile worth a closer look, not the fact that either stock "is healthcare" or "is due." On the other side, AMD at 80 and Arista at 83 aren't broken theses, but both got more extended this week, not less, despite what the price chart alone would suggest. The lesson isn't buy healthcare, sell momentum. It's that price direction and entry quality are two different questions, and this week they split further apart than usual.

Scores in this piece come from the ZonedInOut model. How the score works →

Get the Sunday Brief

One email a week, before the open: what the board did, which calls worked, which didn't, and what changed. Free. No spam, unsubscribe anytime.